Cargando…

Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia

Detalles Bibliográficos
Autores principales:	Wood, Nicholas, Lopez, Laura K., Glover, Catherine, Leeb, Alan, Cashman, Patrick, Deng, Lucy, Macartney, Kristine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854254/ https://www.ncbi.nlm.nih.gov/pubmed/36694479 http://dx.doi.org/10.1016/j.lanwpc.2023.100684

Ejemplares similares

The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021
por: Deng, Lucy, et al.
Publicado: (2022)

Testing for SARS-CoV-2 infection: a key strategy to keeping schools and universities open
por: Koirala, Archana, et al.
Publicado: (2021)

Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia
por: Pillsbury, Alexis J, et al.
Publicado: (2018)

Participant-centred active surveillance of adverse events following immunisation: a narrative review
por: Cashman, Patrick, et al.
Publicado: (2017)

Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance
por: Phillips, Anastasia, et al.
Publicado: (2021)

Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant
por: Lopez, Laura, et al.
Publicado: (2022)

Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them!
por: Gronbeck, Christian, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

When vaccine adverse event reporting generates hope, not fear
por: Chang, Joyce C, et al.
Publicado: (2022)

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
por: Pillsbury, Alexis, et al.
Publicado: (2023)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
por: Waissengrin, Barliz, et al.
Publicado: (2021)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older
por: Pillsbury, Alexis J., et al.
Publicado: (2020)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

The problem of selection bias in studies of pre-mRNA splicing
por: Dwyer, Zachary W., et al.
Publicado: (2023)

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
por: Khan, Zia, et al.
Publicado: (2019)

Emerging links between m(6)A and misregulated mRNA methylation in cancer
por: Jaffrey, Samie R., et al.
Publicado: (2017)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study
por: Jacoby, Peter, et al.
Publicado: (2020)

Adult-onset Still's disease after mRNA COVID-19 vaccine
por: Magliulo, Daniel, et al.
Publicado: (2021)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
por: Heymans, Stephane, et al.
Publicado: (2021)

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19
por: Richardson, Christopher D
Publicado: (2022)

CS-2034 mRNA vaccine: a new option for COVID-19 infection?
por: Zhang, Ruiqi, et al.
Publicado: (2023)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Covid19 Outbreak in Victoria, Australia Update August 1, 2020
por: Boretti, Alberto
Publicado: (2020)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Predictors of confidence and trust in government and institutions during the COVID-19 response in Australia
por: Nickel, Brooke, et al.
Publicado: (2022)

Herpes zoster vaccination in Australia: what’s available and who benefits?
por: Jayasinghe, Sanjay, et al.
Publicado: (2020)

The long and the short of it
por: Petsko, Gregory A
Publicado: (2010)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qs97gpj6na2hs1u1ombaiaaff9